Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 461-470 of 525 results
Nature Communications, 2024 • December 8, 2024
The study identifies SCM-198 as a potential therapeutic agent for advanced acute liver failure (ALF). SCM-198 demonstrates a remarkable 100% survival rate in murine ALF models, even when administered ...
KEY FINDING: SCM-198 treatment resulted in a 100% survival rate in murine ALF models, even when administered 24 hours after ALF was established.
PLoS ONE, 2018 • March 26, 2018
This study investigated the effects of pharmacologic sclerostin inhibition and testosterone administration on muscle atrophy in rats after spinal cord injury (SCI). Sclerostin inhibition did not preve...
KEY FINDING: Sclerostin antibody (Scl-Ab) did not prevent soleus muscle atrophy after spinal cord injury (SCI) in rats.
PLoS ONE, 2018 • August 29, 2018
This study investigated the effects of ursolic acid (UA) on sub-lesional muscle pathology in a mouse model of spinal cord injury (SCI). The study found that UA improves anabolic IGF-1/mTOR signaling, ...
KEY FINDING: Ursolic acid treatment attenuates SCI induced decreases in activated forms of mTOR, and signaling intermediates PI3K, AKT, and S6K.
Neural Regen Res, 2013 • December 1, 2013
This study investigated the protective effect of curcumin on ischemic spinal cord injury in rats. Spinal cord ischemia models were created by ligating the lumbar artery, and curcumin was administered ...
KEY FINDING: Curcumin significantly improved motor function of the rat hind limb after spinal cord ischemia.
Spinal Cord Series and Cases, 2019 • January 1, 2019
This study assessed attitudes toward and knowledge of cannabis among a nationwide sample of people with SCI. Participants largely believed that cannabis use is safe, has potential therapeutic benefits...
KEY FINDING: Most participants believed cannabis is safe, has medicinal benefits, and should be legal.
Frontiers in Oncology, 2019 • February 1, 2019
This systematic review analyzed 33 studies on molecular targeted therapy (MTT) for chordoma, a rare bone malignancy affecting the spine and skull base. The review identified imatinib and erlotinib as ...
KEY FINDING: Imatinib and erlotinib were the most frequently used molecular targeted inhibitors (MTIs) for chordoma.
Adv. Sci., 2018 • July 23, 2018
The study introduces DeepScreen, a deep learning-based drug screening system utilizing convolutional neural networks and flow cytometry single-cell images, to address the limitations of traditional me...
KEY FINDING: DeepScreen demonstrates high accuracy in assessing the efficacy of drugs and nanoformulated drug systems, achieving accuracies of 0.851, 0.864, and 0.908 in testing mixed cells, HEpG2, and A549 cells, respectively.
Future Sci. OA, 2015 • January 1, 2015
Spinal cord regeneration following treatment with a novel membrane-spanning peptide (MSP) expressing the isoleucine-lysine-valine-alanine-valine (IKVAV) epitope was assessed in Balb-c mice. IKVAV-MSP ...
KEY FINDING: IKVAV-MSP group scores increased significantly compared with control groups after 4 weeks of observation (p < 0.05).
bioRxiv preprint, 2023 • September 2, 2023
The study developed a customizable hydrogel platform for local delivery of protein therapeutics, using bioorthogonal SPAAC click chemistry for tunable release rates and compatibility with various prot...
KEY FINDING: The release rate of payloads from the hydrogels can be customized by selecting azidoacids of varying lengths, thereby controlling ester hydrophobicity.
International Journal of Immunopathology and Pharmacology, 2018 • August 28, 2018
Glial scar formation is a complex response to injury in the central nervous system, involving astrocytes, immune cells, and extracellular matrix deposition, which can both inhibit and promote neural r...
KEY FINDING: Glial scar formation involves the activation of resident astrocytes, which surround the lesion core and wall off intact neurons in neurological damages.